On May 29, 2024, Blueprint Medicines published the results of a study whose data suggests that BLU-782 may be a candidate for the prevention of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP).

Blueprint Medicines' study was also featured in BioWorld on June 5, 2024 and in Chemical & Engineering News on June 7, 2024.

As you may remember, on October 16, 2019, Ipsen and Blueprint Medicines announced an exclusive global license agreement to develop and commercialize BLU-782 for the treatment of FOP.

BLU-782 is now known as fidrisertib and is being tested in a Phase 2 FOP clinical trial. You can learn more at ifopa.org/ipn60130. 

Questions about these publications or the FALKON trial? Contact us at [email protected]